The following clinical trial is recruiting participants nationally. FAI is providing information about this study as a service to our constituents.
Study PEP01.09 : Investigational New Drug for Peanut Allergy Using a Skin Delivery SystemResearch sites across the US are looking for a specific category of subjects to complete a research study of the safety and tolerability of an investigational new drug using a skin delivery system for those with a peanut allergy. To qualify, participants must:
- Be between the ages of 18 and 50 years
- Have a physician-diagnosed or a well-documented history of peanut allergy
- Have experienced some severe reactions to peanuts including for example difficulty swallowing, wheezing, feeling of "pending doom," drop of blood pressure, loss of consciousness.
Additional study criteria will be reviewed with study staff at the first study visit.
The study lasts approximately 6 weeks and requires 7 study visits. Participants will receive study-related visits, study-related medical evaluations, and an EpiPen at no cost, plus compensation for time and travel.
Research sites are: Duke University Medical Center, Durham, NC; The National Jewish Medical & Research Center, Denver, CO; Arkansas Children's Hospital Research Institute, Little Rock, AR; Aspen CR, Orem, UT; and CRI Worldwide, Willingboro, NJ.
Find out if you may qualify by contacting:1-877-41-ALLERGY (1-877-412-5537) or visit www.peanutallergytrial.com
No comments:
Post a Comment